Goldman Sachs’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $184K | Sell |
36,275
-346,042
| -91% | -$1.75M | ﹤0.01% | 4753 |
|
|
2025
Q1 | $1.15M | Buy |
382,317
+120,496
| +46% | +$364K | ﹤0.01% | 3713 |
|
|
2024
Q4 | $948K | Buy |
+261,821
| New | +$948K | ﹤0.01% | 3952 |
|
|
2024
Q2 | – | Sell |
-217,233
| Closed | -$424K | – | 4947 |
|
|
2024
Q1 | $424K | Buy |
217,233
+73,663
| +51% | +$144K | ﹤0.01% | 4061 |
|
|
2023
Q4 | $202K | Buy |
+143,570
| New | +$202K | ﹤0.01% | 4323 |
|
|
2022
Q1 | – | Sell |
-18,512
| Closed | -$138K | – | 5917 |
|
|
2021
Q4 | $138K | Buy |
+18,512
| New | +$138K | ﹤0.01% | 5122 |
|
|
2017
Q3 | – | Sell |
-1,582
| Closed | -$75K | – | 4430 |
|
|
2017
Q2 | $75K | Sell |
1,582
-709
| -31% | -$33.6K | ﹤0.01% | 4193 |
|
|
2017
Q1 | $112K | Sell |
2,291
-3,313
| -59% | -$162K | ﹤0.01% | 4089 |
|
|
2016
Q4 | $169K | Sell |
5,604
-1,048
| -16% | -$31.6K | ﹤0.01% | 3949 |
|
|
2016
Q3 | $296K | Buy |
6,652
+4,305
| +183% | +$192K | ﹤0.01% | 3711 |
|
|
2016
Q2 | $91K | Sell |
2,347
-707
| -23% | -$27.4K | ﹤0.01% | 4151 |
|
|
2016
Q1 | $168K | Buy |
3,054
+2,100
| +220% | +$116K | ﹤0.01% | 3855 |
|
|
2015
Q4 | $131K | Sell |
954
-3,292
| -78% | -$452K | ﹤0.01% | 3904 |
|
|
2015
Q3 | $610K | Sell |
4,246
-1,291
| -23% | -$185K | ﹤0.01% | 3187 |
|
|
2015
Q2 | $1.44M | Buy |
+5,537
| New | +$1.44M | ﹤0.01% | 2759 |
|